Radiotherapy: The Next Decade [Abridged]
About half of all cancer cases are treated by radiotherapy and half by surgery; chemotherapy may be used with either method. Improvements in five-year survival have taken place over twenty years in certain diseases (e.g. Hodgkin's disease, from 6% to 78%; teratoma, from 47% to 64%; seminoma, 52% to 94%), but not in breast, lung or stomach cancer. Growing points include combined radiotherapy and planned surgery; prophylactic irradiation to eliminate subclinical metastases; rational combinations of radiotherapy and chemotherapy, when more specific chemotherapeutic drugs become available; changes in radiation dose fractionation from the usual 'daily treatments for several weeks'; and various methods of overcoming the problem of hypoxic, hence radioresistant, cells in tumours. Improvements in physical dose distribution are still being developed.
The three main approaches to eliminating hypoxic cells are:
(1) To treat the patient in a high pressure oxygen tank: Most clinical series have shown little improvement except for a significant decrease in local recurrence of the larynx and pharynx treated with hyperbaric oxygen at Cardiff (Henk etal. 1971) .
(2) To use beams of nuclear particles which kill hypoxic cells almost as readily as oxygenated cells. Fast neutrons have been in use from the MRC cyclotron at Hammersmith Hospital for several years, and a significant improvement in clinical regression has been reported in advanced cancers of the head and neck (25/39 v. 10/36; Catterall 1974) . Neutron generators are in use or are being installed in Holland, USA, Germany and Japan and a new cyclotron is planned for Edinburgh.
Another type ofnuclear particle with favourable properties for radiotherapy is the negative pi meson beam. Such beams not only kill hypoxic cells as neutron beams do, but have the advantage of delivering a high dose to tissues at depth in the body but only a low dose overlying or underlying tissues. Pion generators are built for nuclear physics research and may cost more than £lOM each; but such machines could be used for therapy 24 hours per day without interfering with the nuclear physics work. The logistics of treating certain categories of disease would be difficult but not insuperable. Such machines will be used within the next few years at Los Alamos, Vancouver, Stanford and Zurich.
(3) To use drugs which mimic the effect of oxygen in sensitizing hypoxic cells to conventional radiation: Drugs have recently been developed (Adams 1973 ) which sensitize hypoxic cells, but not well-oxygenated cells, to radiation. (Drugs which sensitize normal tissues equally as much as malignant tissues, such as BUdR, would not, of course, give appreciable gains in therapy.) They are non-toxic and appear to be able to diffuse to the hypoxic cells in tumours without being used up in the metabolic processes of other cells, as oxygen itself is. At present rather large quantities of the drugs appear to be needed at each administration: grammes instead of milligrammes at each radiation session; but the main toxicity problem seems to be nausea. Applications of this type of radiosensitizing drug are to be expected within the next few years.
Finally, if the progress of the past decades is to continue for certain disease sites, a steady improvement of 1-2% per year in cure rate can be expected. It takes a long time to treat say, 2xlOO patients so that an improvement from 50 % to 65 % over a decade can be demonstrated. Dr K D Bagshawe (Charing Cross Hospital, Fulham Palace Road, London W6 8RF) Chemotherapy: The Next Decade The central problem of cancer chemotherapy, present and future, is the selective killing of tumour cells. Such success as has been achieved already is largely based on empiricism but enough progress has been made for some of the operational factors to be defined and a panoramic view of these serves to indicate the more promising lines of development. In this view I shall omit such areas as support therapy, immunological monitoring and randomized therapeutic trials for although these will continue to contribute, I want to focus on chemotherapeutic principles.
Erlich's original concept of molecules that interfere with biochemical processes specific to cancer cells has remained in limbo because biochemical pathways exclusive to cancer cells have not yet been defined. Substantial programmes, notably with USA, have screened several hundred thousand natural and synthetic compounds for potential activity and have contributed most of the 30 or so agents now in clinical use. The useful
